Borrelia Infections: Clinical Trials

10 trials for Borrelia Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 recruiting, 1 withdrawn. 10 Phase 1, 7 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 110Completed 7, Recruiting 2, Withdrawn 1
Phase 27Completed 4, Recruiting 2, Withdrawn 1

Follow Borrelia Infections: new trials by email Literature Review of Borrelia Infections trials Research Report on Borrelia Infections

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ceftriaxone for Post-Treatment Lyme Disease
Ceftriaxone treatment, Placebo - Post-Treatment Lyme Disease Syndrome
Phase 1 / Phase 2WithdrawnHackensack Meridian Health2026-05-142026-05-18
Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Lumbrokinase - Long Covid, Post-treatment Lyme Disease Syndrome
Phase 1 / Phase 2RecruitingIcahn School of Medicine at Mount Sinai1202024-10-092026-03-13
A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age
mRNA-1975, mRNA-1982, Placebo - Lyme Disease
Phase 1 / Phase 2CompletedModernaTX, Inc.8072023-07-262026-07-30
Effects of Psilocybin in Post-Treatment Lyme Disease
Psilocybin - Post-Treatment Lyme Disease, Chronic Lyme Disease
Phase 1CompletedJohns Hopkins University202022-07-012025-08-20
Human Immune Response to Ixodes Scapularis Tick Bites
Xenodiagnosis Ticks, skin biopsy, blood draw - Tick-borne Diseases, Tick Resistance
Phase 1 / Phase 2RecruitingNational Institute of Allergy and Infectious Diseases (NIAID)602022-02-282026-09-22
First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People
2217LS, 0.9% Sodium Chloride (NaCl) - Lyme Disease
Phase 1CompletedMassBiologics442021-02-112022-09-16
Disulfiram: A Test of Symptom Reduction Among Patients With Previously Treated Lyme Disease
Disulfiram - Fatigue, Quality of Life
Phase 1 / Phase 2CompletedResearch Foundation for Mental Hygiene, Inc.112019-07-312025-01-09
Treating Post-Lyme Disease Syndrome With A Novel Nutraceutical
ReaLife+ (RLP), Inert Brown powder - Post-Lyme Disease Syndrome (PLDS)
Phase 1 / Phase 2CompletedOptimal Health Research302019-07-012026-11-16
Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis
VLA15 with Alum, VLA15 without Alum - Lyme Borreliosis, Nervous System
Phase 1CompletedPfizer1792017-01-312023-04-05
Safety, Skin and Plasma Concentration of Azithromycin Dermal Formulation
Application of SHB001 - Lyme Disease
Phase 1 / Phase 2CompletedUniversity of Zurich322010-04-012010-11-19

Narrower conditions

Lyme Disease (7)  ·  Post-Lyme Disease Syndrome (5)  ·  Fatigue (1)  ·  Fatigue Syndrome, Chronic (1)  ·  Lyme Neuroborreliosis (1)  ·  Post-Acute COVID-19 Syndrome (1)  ·  Tick-Borne Diseases (1)

Broader conditions

Bacterial Infections (10)  ·  Bacterial Infections and Mycoses (10)  ·  Gram-Negative Bacterial Infections (10)  ·  Infections (10)  ·  Spirochaetales Infections (10)  ·  Vector Borne Diseases (10)  ·  Tick-Borne Diseases (9)  ·  Chronic Disease (5)  ·  Disease Attributes (5)  ·  Pathologic Processes (5)  ·  Pathological Conditions, Signs and Symptoms (5)  ·  Post-Infectious Disorders (5)  ·  Lyme Disease (3)  ·  Nervous System Diseases (2)

Interventions

Blood Specimen Collection (1)  ·  Disulfiram (1)  ·  Psilocybin (1)  ·  Sodium Chloride (1)  ·  aluminum sulfate (1)  ·  lumbrokinase (1)

Sponsors

Hackensack Meridian Health (1)  ·  Icahn School of Medicine at Mount Sinai (1)  ·  Johns Hopkins University (1)  ·  MassBiologics (1)  ·  ModernaTX, Inc. (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  Optimal Health Research (1)  ·  Pfizer (1)  ·  Research Foundation for Mental Hygiene, Inc. (1)  ·  University of Zurich (1)

Countries

United States (9)  ·  Belgium (1)  ·  Switzerland (1)

Top investigators

Adriana R Marques, M.D. (1)  ·  Albert Garcia-Romeu, PhD (1)  ·  Bindu Balani, MD (1)  ·  Brian A Fallon, MD (1)  ·  David Putrino, PhD, PT (1)

Results publications

PMID 37419129, PMID 40265182, PMID 41741501, PMID 42086599